Finally, many clinical trials are currently testing drugs that inhibit CRMP2 phosphorylation, as CRMP2 is involved in various neurological disorders (Alzheimer’s disease, schizophrenia, cephalic pain, etc.)19. This evidence concerns the gene DPYSL2 and Alzheimer disease.